We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ULVR:LSEUnilever PLC Analysis

Data as of 2026-07-29 - not real-time

£4,925.29

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

Unilever trades at 4,925 pence, comfortably above its 20‑day (4,639 p), 50‑day (4,460 p) and 200‑day (4,694 p) moving averages, while the MACD shows a bullish crossover (line 85.9 vs signal 61.6) and the RSI sits at 66.7, indicating strong momentum without being overbought. Fundamentally, the company delivers a robust 31.9% ROE, a 3.3% dividend yield with a 76% payout, and solid free cash flow of £6.9 bn, but carries a high debt‑to‑equity ratio of 175, highlighting balance‑sheet leverage concerns.
The DCF‑derived fair value of ~2,917 p suggests the stock is priced well above intrinsic estimates, yet market multiples (PE 22.6, forward PE 16.7) and a consensus “Buy” from 15 analysts imply the market may be pricing in growth from the pending $4 bn Thorne acquisition and a resilient consumer‑defensive franchise. The Fear‑Greed Index at 88.9 (“Extreme Greed”) underscores heightened optimism, while volatility of 29.5% and an almost zero beta (0.02) point to limited systematic risk but notable price swings.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Price above key moving averages and bullish MACD signal
  • Strong dividend yield (3.3%) and high ROE (31.9%)
  • Technical upside to resistance around 5,240 p

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Potential valuation gap between DCF fair value and market price
  • Elevated debt‑to‑equity ratio (175) may constrain flexibility
  • Pending Thorne acquisition could unlock incremental earnings

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Resilient consumer‑defensive franchise with global reach
  • Sustainable dividend and strong cash‑flow generation
  • Strategic growth via acquisition (Thorne) and brand portfolio

Key Metrics & Analysis

Financial Health

Profit Margin18.32%
P/E Ratio22.6
ROE31.87%
ROA8.39%
Debt/Equity175.40
P/B Ratio8.1
Op. Cash Flow£8.6B
Free Cash Flow£6.9B

Technical Analysis

TrendNeutral
RSI66.7
Support£3,646.00
Resistance£5,240.00
MA 20£4,638.79
MA 50£4,459.51
MA 200£4,694.43
MACDBullish
VolumeStable
Fear & Greed Index88.91

Valuation

Fair Value£2,916.75
Target Price£5,174.62
Upside/Downside5.06%
GradeOvervalued
TypeBlend
Dividend Yield3.30%

Risk Assessment

Beta0.02
Volatility29.48%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.